Hoth Therapeutics, Inc. (HOTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.4150

-0.0042

(-1.00%)

At close: 04:00PM EDT

0.4140

-0.00

(-0.24%)

After hours:

07:57PM EDT

Advertisement

O
Analyst Forecast
According to 8 analysts, the average rating for HOTH stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 665.00% from the latest price.
Price Target
$3.06
(665.00% upside)
Analyst Consensus: Buy
Chart
Bar chart with 5 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0 to 5.

Created with Highcharts 10.1.0

Strong Sell
Sell
Hold
Buy
Strong
G
If no reverse split , that means more dilution ?
S
When is next pump and dump?
Z
Here are some recent facts :
- Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours. HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft MC tumor model.
- Orphan Drug status granted, successfully completed API manufacturing feasibility.
- Hoth has filed several patent applications to protect this IP throughout the world.
Bullish
L
Who bought those 7M shares for .85 cents?
v
It very painful to watch this stock.
I finally let it go with big loss.
It look to me that it’s heading to delisted or bankruptcy.
k
Any short squeeze on the way?
Bullish
G
0.45 coming
T
On December 30, 2021, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock between November 16, 2021 and December 29, 2021, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol “HOTH.”

The Notification Letter provides that the Company has 180 calendar days, or until June 28, 2022, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by June 28, 2022,
Bearish
D
my 1.28 position is now 0.89 average. now I can relax and wait for news
B
Anything under $1 is a gift from heaven . Load the boat🚀
Bullish
C
So much fuss about preclinical results — Designed to pump before an offering.
n
I heard about HOTH the other day on (http://alert-sounds.com/). It’s looking like an interesting play.
T
HOTH fans no posts for 4 days gooood ... not saying buy just watch $$$$
B
Another rocket launch
Bullish
V
this one legit created huge bag holders in a span of 2 days. i am not making fun of affected people. this was your lesson to learn.
s
Bah. No volume. Back to $PTE. Taking the small gain here with me. Glta
Neutral
N
Reverse Split will have to happen, that nasty Nasdaq requirement. Also, the majority of institutions can't buy under $5. All stocks under $5 are considered "penny" stocks. Long term HOTH should do well, but it is atleast 18 months away from anything significant. They haven't even begun trials.
W
A new beginning!
Bullish
D
whoever bought this yesterday really got scammed!